Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Intellia Therapeutics, Inc.    NTLA

INTELLIA THERAPEUTICS, INC.

(NTLA)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
11/19/2020 11/20/2020 11/23/2020 11/24/2020 11/25/2020 Date
32.26(c) 32.34(c) 34.28(c) 34.81(c) 35.67 Last
1 034 209 856 799 1 024 406 903 229 584 186 Volume
-5.76% +0.25% +6.00% +1.55% +2.47% Change
More quotes
Financials (USD)
Sales 2020 65,5 M - -
Net income 2020 -127 M - -
Net cash position 2020 276 M - -
P/E ratio 2020 -15,1x
Yield 2020 -
Sales 2021 39,2 M - -
Net income 2021 -183 M - -
Net cash position 2021 219 M - -
P/E ratio 2021 -12,0x
Yield 2021 -
Capitalization 2 057 M 2 057 M -
EV / Sales 2020 27,2x
EV / Sales 2021 46,9x
Nbr of Employees 270
Free-Float 83,4%
More Financials
Company
Intellia Therapeutics, Inc. is a genome editing company. The Company is focused on developing therapeutics utilizing a biological tool known as CRISPR/Cas9. The CRISPR/Cas9 genome editing system includes two components: the Cas9 protein and the guide RNA sequence. The Cas9 protein acts like a pair of molecular scissors that initiates the natural cellular repair process to knockout, repair or insert a gene. The guide... 
More about the company
Notations Surperformance© of Intellia Therapeutics, Inc.
Trading Rating : Investor Rating :
More Ratings
All news about INTELLIA THERAPEUTICS, INC.
11/11INTELLIA THERAPEUTICS : Receives Grant to Develop Curative CRISPR/Cas9 In Vivo S..
AQ
11/11Intellia Therapeutics Receives Grant to Develop Curative CRISPR/Cas9 In Vivo ..
GL
11/10INTELLIA THERAPEUTICS : Doses First Patient in Landmark CRISPR Cas9 Clinical Tri..
AQ
11/09INTELLIA THERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits (f..
AQ
11/09INTELLIA THERAPEUTICS : Doses First Patient in Landmark CRISPR/Cas9 Clinical Tri..
AQ
11/09INTELLIA THERAPEUTICS : Doses First Patient in Landmark CRISPR/Cas9 Clinical Tri..
AQ
11/09Intellia Therapeutics Doses First Patient in Landmark CRISPR/Cas9 Clinical Tr..
GL
11/05INTELLIA THERAPEUTICS : Management's Discussion and Analysis of Financial Condit..
AQ
11/05INTELLIA THERAPEUTICS, INC. : Results of Operations and Financial Condition, Fin..
AQ
11/05INTELLIA THERAPEUTICS : Announces Third Quarter 2020 Financial Results
AQ
11/05Intellia Therapeutics Announces Third Quarter 2020 Financial Results
GL
10/29INTELLIA THERAPEUTICS : to Hold Conference Call to Discuss Third Quarter 2020 Ea..
AQ
10/29Intellia Therapeutics to Hold Conference Call to Discuss Third Quarter 2020 E..
GL
10/20INTELLIA THERAPEUTICS : Receives Authorization to Initiate Phase 1 Clinical Tria..
AQ
10/19INTELLIA THERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits (f..
AQ
More news
News in other languages on INTELLIA THERAPEUTICS, INC.
2018WALL STREET STOCK EXCHANGE : Wall Street finit dans le désordre, le pétrole pèse
More news
Chart INTELLIA THERAPEUTICS, INC.
Duration : Period :
Intellia Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends INTELLIA THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 14
Average target price 35,96 $
Last Close Price 34,81 $
Spread / Highest target 65,2%
Spread / Average Target 3,31%
Spread / Lowest Target -36,8%
EPS Revisions
Managers
NameTitle
John M. Leonard President, Chief Executive Officer & Director
Frank A. G. M. Verwiel Chairman
Andrew D. Schiermeier Chief Operating Officer
Glenn Goddard Executive VP, Chief Financial & Accounting Officer
Laura Sepp-Lorenzino Chief Scientific Officer & Executive VP
Sector and Competitors
1st jan.Capitalization (M$)
INTELLIA THERAPEUTICS, INC.137.29%2 057
LONZA GROUP AG56.17%44 950
MODERNA, INC.403.89%39 001
CELLTRION, INC.82.32%36 284
IQVIA HOLDINGS INC.11.32%32 977
SEAGEN INC.44.08%29 684